Mustang Bio Announces License Agreement with CSL Behring for the Cytegrity™ Stable Producer Cell Line for the Production of MB-107 Lentiviral Gene Therapy

Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that it has entered into a license agreement with CSL Behring for the Cytegrity™ stable producer cell line developed and used by St. Jude Children’s Research Hospital (“St. Jude”). Cytegrity™ stable producer cell line will be used to produce the viral vector for Mustang Bio’s MB-107 lentiviral gene therapy program for the treatment of X-linked severe combined immunodeficiency (XSCID). Mustang licensed MB-107 from St. Jude in August 2018.

Bluebird gene therapy approved in Europe in first for severe blood disorder

Zynteglo is Bluebird's first drug to be approved and is the first gene therapy to be cleared for use in transfusion-dependent beta-thalassemia. 

Its marketing authorization from the European Commission follows landmark approvals from the Food and Drug Administration for Novartis' Zolgensma and Spark Therapeutics' Luxturna, which respectively treat spinal muscular atrophy and a type of inherited eye disease. 

Former KKR execs bring in $2.5B for China-focused funds

Private equity firm DCP Capital has reportedly raised some $2.5 billion for its inaugural US dollar- and yuan-denominated funds. That total includes more than $2 billion for DCP Capital Partner I, with the rest going to a yuan vehicle raised at the same time. Among the LPs, per reports: Singaporean investors GIC and Temasek, along with Canadian public pension fund Caisse de depot et placement du Quebec.

China’s Burning Rock Biotech completes Series C financing of RMB 850 million

China’s Burning Rock Biotech completes Series C financing of RMB 850 million

Burning Rock Biotech, which was founded in 2014 and focuses on NGS (Next-Generation Sequencing) diagnostics solutions for precision medicine in oncology, today announced the closing of the Series C financing totaling RMB 850 million. The financing was led by GIC, followed by LYFE Capital, CMB International Capital, Lilly Asia Ventures (LAV), Sequoia Capital China and T&Brothers Capital.